Fig. 2

SALL4 promotes ccRCC cells growth in vitro and in vivo. a Western blot analyses of SALL4 expression in ccRCC cells stably expressing indicated shRNA (shNC, negative control shRNA; sh#1 and sh#2, shRNAs targeting SALL4). b The CCK-8 assays were performed in ACHN and 786-O cells treated with indicated shRNA. c Colony formation assays in ACHN and 786-O cells with indicated shRNA treatment. d Cell cycle distribution was examined by flow cytometry in ACHN and 786-O cells treated as indicated. e Cellular senescence was detected by SA-β-gal staining in ACHN and 786-O cells treated with shNC and shSALL4 (scale bar, 50 μm). f-i Scatter plot analyses were performed to determine the correlation between SALL4 and CCNE1 (f), CDK3 (g), E2F1 (h) and RB1 (i) mRNA expression levels in 533 ccRCC patients from TCGA database. Data were analyzed via LinkedOmics bioinformatics. j The image of dissected tumors from nude mice. k, l The growth curve (k) and their weights (l) of subcutaneous tumors formed by 786-O cells with indicated treatment. * P < 0.05, ** P < 0.001 and *** P < 0.001